Literature DB >> 31607545

Programmable Inhibition and Detection of RNA Viruses Using Cas13.

Catherine A Freije1, Cameron Myhrvold2, Chloe K Boehm3, Aaron E Lin4, Nicole L Welch4, Amber Carter3, Hayden C Metsky5, Cynthia Y Luo6, Omar O Abudayyeh7, Jonathan S Gootenberg8, Nathan L Yozwiak6, Feng Zhang9, Pardis C Sabeti10.   

Abstract

The CRISPR effector Cas13 could be an effective antiviral for single-stranded RNA (ssRNA) viruses because it programmably cleaves RNAs complementary to its CRISPR RNA (crRNA). Here, we computationally identify thousands of potential Cas13 crRNA target sites in hundreds of ssRNA viral species that can potentially infect humans. We experimentally demonstrate Cas13's potent activity against three distinct ssRNA viruses: lymphocytic choriomeningitis virus (LCMV); influenza A virus (IAV); and vesicular stomatitis virus (VSV). Combining this antiviral activity with Cas13-based diagnostics, we develop Cas13-assisted restriction of viral expression and readout (CARVER), an end-to-end platform that uses Cas13 to detect and destroy viral RNA. We further screen hundreds of crRNAs along the LCMV genome to evaluate how conservation and target RNA nucleotide content influence Cas13's antiviral activity. Our results demonstrate that Cas13 can be harnessed to target a wide range of ssRNA viruses and CARVER's potential broad utility for rapid diagnostic and antiviral drug development.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arenavirus; CRISPR; Cas13; Cas13-based detection; RNA interference; RNA viruses; antiviral; crRNA design; influenza virus; multiplexing

Mesh:

Substances:

Year:  2019        PMID: 31607545     DOI: 10.1016/j.molcel.2019.09.013

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  102 in total

1.  Structural basis for self-cleavage prevention by tag:anti-tag pairing complementarity in type VI Cas13 CRISPR systems.

Authors:  Beibei Wang; Tianlong Zhang; Jun Yin; You Yu; Wenhao Xu; Jianping Ding; Dinshaw J Patel; Hui Yang
Journal:  Mol Cell       Date:  2021-01-19       Impact factor: 17.970

Review 2.  Advances in gene therapy for neurogenetic diseases: a brief review.

Authors:  Ying-Xuan Xie; Wen-Qi Lv; Yi-Kun Chen; Shunyan Hong; Xiang-Ping Yao; Wan-Jin Chen; Miao Zhao
Journal:  J Mol Med (Berl)       Date:  2021-11-27       Impact factor: 4.599

Review 3.  RNA-targeting CRISPR systems from metagenomic discovery to transcriptomic engineering.

Authors:  Aaron A Smargon; Yilan J Shi; Gene W Yeo
Journal:  Nat Cell Biol       Date:  2020-02-03       Impact factor: 28.824

4.  Diversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing.

Authors:  Sarah Balderston; Gabrielle Clouse; Juan-José Ripoll; Grace K Pratt; Giedrius Gasiunas; Jens-Ole Bock; Eric Paul Bennett; Kiana Aran
Journal:  CRISPR J       Date:  2021-06

5.  Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes.

Authors:  Chunlong Xu; Yingsi Zhou; Qingquan Xiao; Bingbing He; Guannan Geng; Zikang Wang; Birong Cao; Xue Dong; Weiya Bai; Yifan Wang; Xiang Wang; Dongming Zhou; Tanglong Yuan; Xiaona Huo; Jinsheng Lai; Hui Yang
Journal:  Nat Methods       Date:  2021-05-03       Impact factor: 28.547

Review 6.  HEPN RNases - an emerging class of functionally distinct RNA processing and degradation enzymes.

Authors:  Monica C Pillon; Jacob Gordon; Meredith N Frazier; Robin E Stanley
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-12-22       Impact factor: 8.250

Review 7.  CRISPR/Cas technology as a promising weapon to combat viral infections.

Authors:  Carmen Escalona-Noguero; María López-Valls; Begoña Sot
Journal:  Bioessays       Date:  2021-02-11       Impact factor: 4.345

8.  Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells.

Authors:  Alejandro Méndez-Mancilla; Hans-Hermann Wessels; Mateusz Legut; Anastasia Kadina; Megumu Mabuchi; John Walker; G Brett Robb; Kevin Holden; Neville E Sanjana
Journal:  Cell Chem Biol       Date:  2021-08-02       Impact factor: 8.116

9.  Efficient RNA Virus Targeting via CRISPR/CasRx in Fish.

Authors:  Qing Wang; Yun Liu; Chong Han; Min Yang; Fengqi Huang; Xuzhuo Duan; Shaowen Wang; Yepin Yu; Jiaxin Liu; Huirong Yang; Danqi Lu; Huihong Zhao; Yong Zhang; Qiwei Qin
Journal:  J Virol       Date:  2021-09-09       Impact factor: 5.103

Review 10.  Functional Features and Current Applications of the RNA-Targeting Type VI CRISPR-Cas Systems.

Authors:  Vanja Perčulija; Jinying Lin; Bo Zhang; Songying Ouyang
Journal:  Adv Sci (Weinh)       Date:  2021-05-05       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.